ocean biomedical inc - OCEA

OCEA

Close Chg Chg %
0.00 -0.00 -33.33%

Pre-Market

0.00

0.00 (33.33%)

Volume: 127.34K

Last Updated:

Dec 30, 2025, 3:48 PM EDT

Company Overview: ocean biomedical inc - OCEA

OCEA Key Data

Open

$0.00

Day Range

0.00 - 0.00

52 Week Range

0.00 - 0.76

Market Cap

$0.00

Shares Outstanding

232.37M

Public Float

208.41M

Beta

1.33

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.91

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

158.44K

 

OCEA Performance

1 Week
 
0.00%
 
1 Month
 
-85.19%
 
3 Months
 
-92.98%
 
1 Year
 
-99.93%
 
5 Years
 
N/A
 

OCEA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About ocean biomedical inc - OCEA

Ocean Biomedical, Inc. is a biopharmaceutical company. It engages in the business of discovering and developing therapeutic products in oncology, fibrosis, infectious diseases and inflammation. The company was founded by Chirinjeev Kathuria in June 2021 and is headquartered in Providence, RI.

OCEA At a Glance

Ocean Biomedical, Inc.
55 Claverick Street
Providence, Rhode Island 02903
Phone 1-401-444-7375 Revenue 0.00
Industry Pharmaceuticals: Major Net Income -9,480,000.00
Sector Health Technology Employees 7
Fiscal Year-end 12 / 2025
View SEC Filings

OCEA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -8.237
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.521

OCEA Efficiency

Revenue/Employee N/A
Income Per Employee -1,354,285.714
Receivables Turnover N/A
Total Asset Turnover N/A

OCEA Liquidity

Current Ratio 0.024
Quick Ratio 0.024
Cash Ratio 0.007

OCEA Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -296.111
Return on Equity N/A
Return on Total Capital 11.658
Return on Invested Capital N/A

OCEA Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital -20.045
Total Debt to Total Assets 1,807.095
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Ocean Biomedical Inc - OCEA

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
- - - -
-
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- - - -
-
Depreciation
- - - -
-
Amortization of Intangibles
- - - -
-
COGS Growth
- - - -
-
Gross Income
- - - -
-
Gross Income Growth
- - - -
-
Gross Profit Margin
- - - -
-
2021 2022 2023 2024 5-year trend
SG&A Expense
566.56K 2.48M 9.31M 3.80M
Research & Development
- - 709.00K 26.00K
-
Other SG&A
566.56K 2.48M 8.61M 3.77M
SGA Growth
- +338.02% +275.32% -59.22%
Other Operating Expense
- - - -
-
Unusual Expense
- - 40.03M (1.65M)
-
EBIT after Unusual Expense
(566.56K) (2.48M) (49.35M) (2.15M)
Non Operating Income/Expense
2.45K 1.52M (63.35M) (5.28M)
Non-Operating Interest Income
- - 2.45K 1.52M
-
Equity in Earnings of Affiliates
- - (708.00K) (3.30M)
-
Interest Expense
- 691 1.76M 2.05M
Interest Expense Growth
- - +254,892.76% +16.12%
-
Gross Interest Expense
- 691 1.76M 2.05M
Interest Capitalized
- - - -
-
Pretax Income
(564.11K) (958.43K) (114.47M) (9.48M)
Pretax Income Growth
- -69.90% -11,843.07% +91.72%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - (708.00K) (3.30M)
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(564.11K) (958.43K) (114.47M) (9.48M)
Minority Interest Expense
- - - -
-
Net Income
(564.11K) (958.43K) (114.47M) (9.48M)
Net Income Growth
- -69.90% -11,843.07% +91.72%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(564.11K) (958.43K) (114.47M) (9.48M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(564.11K) (958.43K) (114.47M) (9.48M)
EPS (Basic)
-0.0426 -0.0725 -4.3536 -0.3447
EPS (Basic) Growth
- -70.19% -5,904.97% +92.08%
Basic Shares Outstanding
13.22M 13.22M 26.29M 27.50M
EPS (Diluted)
-0.0426 -0.0725 -4.3536 -0.3447
EPS (Diluted) Growth
- -70.19% -5,904.97% +92.08%
Diluted Shares Outstanding
13.22M 13.22M 26.29M 27.50M
EBITDA
(566.56K) (2.48M) (9.31M) (3.80M)
EBITDA Growth
- -338.02% -275.32% +59.22%
EBITDA Margin
- - - -
-

Ocean Biomedical Inc in the News